What are you looking for?

Results

A total of 0 Companies

Overview

Employees
1-10 employees
Type
Privately Held
Revenue
NA
Competitors
N/A
Headquarters
Buffalo, NY
Founded
2012
Category
Disrupting Cancer with Immunotherapy

Our vision, to disrupt cancer with the development of highly innovative immunotherapies aimed at increasing patient survival rates MimiVax is a privately held, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutic vaccines and targeted therapies for the treatment of cancer. SurVaxM, our lead immunotherapeutic vaccine, has completed a Phase 2 clinical trial in adults with newly diagnosed glioblastoma. Additional indications are being evaluated through Phase 1 clinical trials in multiple myeloma combination with REVLIMID® (lenalidomide) as well as Phase 1 in Neuro-Endocrine Tumors (NET)

Reviews

See All Reviews
Similar companies